Ausai takes you to collect the wisdom of Australia’s wealth
Maurie Stang, photo/AFR
In the field of medical technology investment in Australia, there is a “godfather” figure, he is Maurie Stang, the founder of Nanosonics, a well-known Australian medical disinfection equipment company.
Nanosonics (ASX: NAN) was founded by him 21 years ago. It was listed on the ASX in 2007 and has a current market value of more than 1 billion. Stang served as chairman of the company until July this year.
Now his company, Gryphon Capital, has formed a joint venture, EnviroGuard, with Australian air purification start-up VBreathe, focused on helping businesses create a safer work environment by purifying the air to reduce the risk of germs spreading.
Speaking to The Australian Financial Review (AFR), Stang said Gryphon Capital had been looking at the next steps in corporate environmental and social governance and realised there were many opportunities in the post-pandemic world of “healthy buildings”.
After meeting with VBreathe CEO Mohit Sharma, Stang was impressed with the company’s engineering and technical teams, but he was more interested in offering services to businesses.
Therefore, the two decided to set up EnviroGuard, hoping to develop VBreathe’s technology to a level suitable for enterprise applications.
Maurie Stang herself has over 30 years of successful experience in the Australian healthcare market and is a well-respected business executive, entrepreneur and investor.
Maurie Stang, photo/AFR
The industry describes Maurie Stang as a “medical science and technology giant”. In addition to Nanosonics, he is also the chairman of Aeris Environmental, another Australian listed purification technology company, and a director of Vectus Biosystems, a listed pharmaceutical research organization.
The latter has been working on gastrointestinal peptide drugs to treat diseases of cardiovascular, pulmonary and liver fibrosis. After reaching confidentiality and material transfer agreements with a series of global companies this year, Stang believes that once the agreement is reached, the company’s market value may increase by more than 10 times.
In addition, he also founded a dental equipment company and established a joint venture in Australia with Henry Schein (NASDAQ: HSIC), which is listed on NASDAQ and has annual global sales of nearly US$10 billion, which has become the largest dental equipment company in Australia. product supplier.
Australia’s air purification “first person”
This time, Stang’s Gryphon Capital and VBreathe each invested half of the joint venture EnviroGuard, and Stang himself will serve as the chairman of the joint venture.
The company will leverage and extend VBreathe’s technology to create a four-layer air filtration system with integrated sensors designed to improve air quality and indoor sanitation.
The technology integrates a patented sanitizing gel based on natural compounds and a high-efficiency particulate filter that captures tiny particles.
Unlike many purification technologies on the market, VBreathe does not need to be unoccupied when it is in operation.
Vbreathe Tasman air purifier with built-in patented sanitizing gel
Stang said the joint venture will build on existing technology, develop entirely new features, and use a new pricing model. He believes that although the combination of air purification and cloud applications is not new, VBreahte’s products have made significant progress in its own field.
Pricing for the new equipment has yet to be determined by the joint venture, but it is tentatively planned for around $2000 each, mainly for conference rooms or high-traffic areas, where germs can easily spread.
In addition to office space, Stang expects the device will also attract healthcare businesses such as dental and general practice.
Although VBreathe’s device is currently only suitable for smaller spaces, in the future the company will combine it with other technologies to cover larger open spaces.
While EnviroGuard is targeting enterprise customers, VBreathe will continue to focus on the consumer market.
More than 10,000 units of VBreathe’s Air Evolution antivirus device, the Tasman, have been sold since its launch, priced at $690 apiece.
VBreathe founder and CEO Mohit Sharma holding a Tasman device
The development of Tasman took five years, and laboratories such as Eurofins have tested it and the results show that after two hours of use, Tasman can reduce the spread of the new coronavirus by 99.9%.
The device has a portable design, charges via a USB-C connection, looks a lot like a speaker, and its appearance is also loved by many consumers.
According to Sharma, “We were the first to combine active and passive cleaning technologies in filtration.”
VBreathe’s investors include Mark McConnell of the Citadel Group, an international enterprise software group. This member of the Australian Young Rich List is also optimistic about VBreathe’s technological innovation and technology going overseas.
Boman Financial Group (BMYG) is also one of VBreathe’s important early-stage investment institutions.
VBreathe launched its global market last year and in December was awarded the NSW Government’s R&D Innovation Districts Challenges.
This collaboration with Stang’s team, Sharma said, will provide VBreathe with a unique opportunity to expand the company’s emerging technology into the enterprise and healthcare segments. The market is expected to grow in excess of A$4 billion annually by 2028.
Editor: Shadow Wu
(The pictures without the source indicated in the text are all used by Shutterstock, Inc. authorized by Aocai, and reprinting the pictures alone may cause legal risks.)